69839-83-4 | Didox

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$24.00	$17.00
5mg	98%	in stock	$74.00	$52.00
100mg	98%	in stock	$96.00	$67.00
250mg	98%	in stock	$162.00	$113.00

Description

• Catalog Number: AC55535
• Chemical Name: Didox
• CAS Number: 69839-83-4
• Molecular Formula: C7H7NO4
• Molecular Weight: 169.1348
• MDL Number: MFCD01667810
• SMILES: ONC(=O)c1ccc(c(c1)O)O
• NSC Number: 324360

Computed Properties

• Complexity: 173
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 12
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 1
• XLogP3: 0.4

Literature

• 3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.

  Chemico-biological interactions 20150525

• Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.

  Antiviral research 20131001

• Paradoxical response to prophylactic Didox (N-3, 4 trihydroxybenzamide) treatment in murine cytomegalovirus-infected mice.

  Antiviral therapy 20110101

• Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model.

  Comparative medicine 20091201

• Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.

  British journal of haematology 20061001

• Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation.

  Microcirculation (New York, N.Y. : 1994) 20060901

• Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.

  International journal of cancer 20050910

• Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury.

  The Journal of pharmacology and experimental therapeutics 20050701

• Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.

  Antiviral research 20050101

• Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.

  Nucleosides, nucleotides & nucleic acids 20041001

• Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.

  Cancer chemotherapy and pharmacology 20040801

• In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.

  Antiviral research 20040601

• Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.

  Cancer chemotherapy and pharmacology 20030701

• Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.

  Biochemical pharmacology 20030115

• Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea.

  Antiviral research 20021101

• Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea.

  Antiviral chemistry & chemotherapy 20020901

• Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

  Cancer biology & therapy 20020101

• Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.

  Experimental hematology 20010501

• In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.

  Stem cells (Dayton, Ohio) 19990101

• Selective inhibition of l kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds.

  Virology 19970804

• Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.

  Journal of medicinal chemistry 19970314